Onxeo SA (0NWK.L)
| Previous close | 0.7305 |
| Open | 0.5825 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.5825 - 0.5825 |
| 52-week range | 0.5825 - 0.5825 |
| Volume | 2,370 |
| Avg. volume | N/A |
| Market cap | 32.914M |
| Beta (5Y monthly) | 1.49 |
| PE ratio (TTM) | 58.25 |
| EPS (TTM) | 0.0100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Onxeo Reports Its 2021 Half-Yearly Financial Results and Provides an Update on Its Activities
PARIS, July 29, 2021--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), « Onxeo », a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, today announced its consolidated half-yearly financial results to June 30, 2021 and provides an update on its activities.
- Globe Newswire
Onxeo Announces the Appointment of Dr. Shefali Agarwal as the Company’s Chairwoman of the Board
Danièle Guyot-Caparros, outgoing Chairwoman, remains an independent member of the Board of Directors and Chair of the Audit Committee Paris (France), July 29, 2021 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), « Onxeo », a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, today announced the appointment of Dr Shefali Agarwal as the Company’s Chairwoman of the
- Business Wire
Summary of Onxeo’s Liquidity Contract with Kepler Cheuvreux
PARIS, July 13, 2021--Regulatory News: Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo (Paris:ALONX) (NASDAQ OMX:ALONX) shares, the following resources were listed in the liquidity account as at June 30, 2021, settlement date:
